Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapy

Lee, E. J.; Deavers, Michael T.; Hughes, John I.; Lee, J. H.; Kavanagh, John J.

doi:10.1111/j.1525-1438.2006.00206.x

Cited by 21 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, adverse effects or toxicity still occurs. Although ≥90% of serous BOTs are estrogen receptor-positive [ 52 53 ], there are no detailed studies, only case reports, testing the effect of tamoxifen, leuprolide, or anastrozole on these tumors [ 54 ].…”

Section: Is Postoperative Adjuvant Chemotherapy Necessary?mentioning

confidence: 99%

Controversies in borderline ovarian tumors

Seong

Kim

et al. 2015

J Gynecol Oncol

View full text Add to dashboard Cite

Borderline ovarian tumors (BOTs) represent about 15% to 20% of all ovarian malignancies and differ from invasive ovarian cancers (IOCs) by many characters. Historically, standard management of BOT is peritoneal washing cytology, hysterectomy, bilateral salpingo-oophorectomy, omentectomy, complete peritoneal resection of macroscopic lesions; in case of mucinous BOTs, appendectomy should be performed. Because BOTs are often diagnosed at earlier stage, in younger age women and have better prognosis, higher survival rate than IOCs, fertility-sparing surgery is one of the option to preserve childbearing capacity. The study of such conservative surgery is being released, and still controversial. After surgery, pregnancy and ovarian induction followed by in vitro fertilization are also significant issues. In surgery, laparoscopic technique can be used by a gynecologic oncology surgeon. So far postoperative chemotherapy, radiotherapy and hormone therapy are not recommended. We will discuss controversial issues of BOTs on this review and present the outline of the management of BOTs.

show abstract

Section: Is Postoperative Adjuvant Chemotherapy Necessary?mentioning

confidence: 99%

Controversies in borderline ovarian tumors

Seong

Kim

et al. 2015

J Gynecol Oncol

View full text Add to dashboard Cite

show abstract

“…For example, borderline tumors, up to 90% of which express ER (59) , would presumably be sensitive to AI therapy. Recently, we reported an unusual case in which anastrozole treatment induced complete remission of a metastatic colon mucosa lesion arising from an ovarian borderline tumor (190) . In our ongoing phase II trial of letrozole in ovarian borderline or low-grade tumors (189) , the preliminary results from 13 evaluable patients showed a response rate of 0% and an SD rate of 38.5% by radiologic evaluation, and a CR or PR rate of 15.4% and an SD rate of 38.5% by CA125 evaluation.…”

Section: Clinical Studiesmentioning

confidence: 99%

Aromatase inhibitors in ovarian cancer: is there a role?

Li¹,

Hu²,

Fu³

et al. 2008

International Journal of Gynecological Cancer

Self Cite

View full text Add to dashboard Cite

Estrogen plays a role in ovarian tumorigenesis. Aromatase is the enzyme required for the synthesis of estrogen via conversion of androgen to estrogen, which is the major source of estrogen in postmenopausal women. Aromatase is present in normal ovaries and other tissues (e.g., fat and muscle) as well as in 33-81% tumor tissues of ovarian cancer. Aromatase inhibitors (AIs) block estrogen synthesis by inhibiting aromatase activity. In patients with recurrent ovarian cancer, single-agent AI therapy has been shown to elicit clinical response rates of up to 35.7% and stable disease rates of 20-42%. Given the limited treatment options for recurrent ovarian cancer and the favorable safety profile and convenient use, AI is a rational option for prolonging platinum-free interval in recurrent ovarian cancer. Further studies are required to determine the efficacy of combination treatment with AIs and biological agents, determine the benefit of AIs for treating special types of ovarian cancer (e.g., endometrioid type), and identify biomarkers for targeted patient selection. This review summarizes the current epidemiologic, preclinical, and clinical data regarding estrogen's role in ovarian cancer, the expression and regulation of aromatase in this disease, the development and characteristics of the three generations of AIs, and the preclinical and clinical studies of AIs in the treatment of ovarian cancer.

show abstract

“…In patients undergoing primary pelvic clearance, the rate of recurrence is 2 % -13 %; the major site of recurrence is the ab-dominal cavity owing to the exfoliation of tumor cells [1 -3]. Recurrence with colorectal involvement is exceedingly rare, with only one case report of metastasis to the sigmoid colon 7 years after primary debulking surgery similar to the present case [4]. However, borderline ovarian tumors are slow growing, and 85 % of recurrences Recurrent borderline ovarian tumor presenting as a pedunculated polyp at colonoscopy Fig.…”

mentioning

confidence: 50%

Recurrent borderline ovarian tumor presenting as a pedunculated polyp at colonoscopy

et al. 2010

View full text Add to dashboard Cite

A 69-year-old woman with a positive fecal occult blood test was referred for further investigations. She had been diagnosed as having a borderline serous ovarian tumor 8 years earlier, for which she had undergone complete debulking surgery. The tumor had originated in the left ovary and a pathological examination had revealed that it was confined to the left ovary, without capsule invasion. The patient was followed up for 7 years after the surgery without any evidence of recurrence. Colonoscopy showed a hyperemic, polypoid lesion, 10 cm from the anal verge (• " Fig. 1) but the biopsy findings were nonspecific. A computed tomography scan confirmed the presence of an intraluminal lesion in the rectum, and submucosal invasion was suspected. To rule out the possibility of recurrence of the borderline tumor or a primary rectal tumor, the patient underwent an exploratory laparotomy. There was no evidence of either carcinomatosis in the abdomen or involvement of adjacent organs. A low anterior resection was carried out with an end-to-end colorectostomy. The resected specimen included the pedunculated rectal polyp, which had invaded the entire rectal wall but was limited to the rectal serosa (• " Fig. 2). On pathological review, the tumor was determined to be a borderline serous malignant tumor (• " Fig. 3 a) and the findings were identical to those of tissue specimens taken from the original borderline ovarian tumor (• " Fig. 3 b). Since surgery, the patient has been doing well with no evidence of recurrence for 18 months.

show abstract

Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapy

Cited by 21 publications

References 46 publications

Controversies in borderline ovarian tumors

Controversies in borderline ovarian tumors

Aromatase inhibitors in ovarian cancer: is there a role?

Recurrent borderline ovarian tumor presenting as a pedunculated polyp at colonoscopy

Contact Info

Product

Resources

About